Posts

Posted on

M.D.C. Holdings Reports Selected Preliminary 2020 Fourth Quarter Results

PR Newswire

DENVER, Jan. 6, 2021 /PRNewswire/ — M.D.C. Holdings, Inc. (NYSE: MDC), one of the nation’s leading homebuilders, reported selected preliminary results for the 2020 fourth quarter. These results are preliminary and unaudited.


2020 Fourth Quarter Highlights and Comparisons to 2019 Fourth Quarter (preliminary and unaudited)

New home deliveries increased 7% to 2,564 from 2,389  

•

Average sales price of approximately $461,000

Net new home orders increased 72% to 2,708 from 1,574

•

Monthly sales absorption pace increased 67% to 4.7

Homes in backlog increased 75% to 6,655 from 3,801

•

Dollar value of backlog increased 87% to $3.26 billion

As previously announced, MDC will release its 2020 fourth quarter earnings before the market opens on Tuesday, February 2, 2021. MDC will host a teleconference the same day at 12:30 pm ET. 


About MDC

M.D.C. Holdings, Inc. was founded in 1972. MDC’s homebuilding subsidiaries, which operate under the name Richmond American Homes, have built and financed the American Dream for more than 210,000 homebuyers since 1977.  MDC’s commitment to customer satisfaction, quality and value is reflected in each home its subsidiaries build. MDC is one of the largest homebuilders in the United States. Its subsidiaries have homebuilding operations across the country, including the metropolitan areas of Denver, Colorado Springs, Salt Lake City, Las Vegas, Phoenix, Tucson, Riverside–San Bernardino, Los Angeles, San Diego, Orange County, San Francisco Bay Area, Sacramento, Washington D.C., Baltimore, Orlando, Jacksonville, Seattle and Portland. MDC’s subsidiaries also provide mortgage financing, insurance and title services, primarily for Richmond American homebuyers, through HomeAmerican Mortgage Corporation, American Home Insurance Agency, Inc. and American Home Title and Escrow Company, respectively. M.D.C. Holdings, Inc. is traded on the New York Stock Exchange under the symbol “MDC.” For more information, visit www.mdcholdings.com.


Forward-Looking Statements

Certain statements in this release, including any statements regarding our business, financial condition, results of operation, cash flows, strategies and prospects, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of MDC to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among other things, (1) general economic conditions, including the impact of the COVID-19 pandemic, changes in consumer confidence, inflation or deflation and employment levels; (2) changes in business conditions experienced by MDC, including restrictions on business activities resulting from the COVID-19 pandemic, cancellation rates, net home orders, home gross margins, land and home values and subdivision counts; (3) changes in interest rates, mortgage lending programs and the availability of credit; (4) changes in the market value of MDC’s investments in marketable securities; (5) uncertainty in the mortgage lending industry, including repurchase requirements associated with HomeAmerican Mortgage Corporation’s sale of mortgage loans (6) the relative stability of debt and equity markets; (7) competition; (8) the availability and cost of land and other raw materials used by MDC in its homebuilding operations; (9) the availability and cost of performance bonds and insurance covering risks associated with our business; (10) shortages and the cost of labor; (11) weather related slowdowns and natural disasters; (12) slow growth initiatives; (13) building moratoria; (14) governmental regulation, including orders addressing the COVID-19 pandemic, the interpretation of tax, labor and environmental laws; (15) terrorist acts and other acts of war; (16) changes in energy prices; and (17) other factors over which MDC has little or no control. Additional information about the risks and uncertainties applicable to MDC’s business is contained in MDC’s most recent annual report on Form 10-K and our subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.  All forward-looking statements made in this press release are made as of the date hereof, and the risk that actual results will differ materially from expectations expressed in this press release will increase with the passage of time. MDC undertakes no duty to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in our subsequent filings, releases or webcasts should be consulted.

 

Cision View original content:http://www.prnewswire.com/news-releases/mdc-holdings-reports-selected-preliminary-2020-fourth-quarter-results-301202018.html

SOURCE M.D.C. Holdings, Inc.

Posted on

Bespoke Extracts Announces Special CBD Promotional Offers and Continued Expansion of Superstar Team of Brand Ambassadors

SUNNY ISLES, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) — Bespoke Extracts, Inc. (OTC Pink: BSPK), producer of high quality, hemp-derived CBD products, today announced its latest special promotional campaign providing for Bespoke CBD customers to receive a free face mask for all purchases under $100 and a free mask and baseball cap for all purchases of $100 or more. The special promotion will run indefinitely and applies to all Sports’ and Women’s CBD formulations sold in the Company’s ecommerce store, found at https://bespokeextracts.com/shop/.

In other news, Bespoke announced that both Bare Knuckle Fighting Championship fighter, Ulysses “The Monster” Diaz, and professional WWE fighter Ashley Mae Serbera, aka Dana Brooke, are the latest elite athletes to join Bespoke’s fast growing team of brand ambassadors. In December 2020, Diaz’s three-second knockout broke the world record for fastest in bare knuckle boxing history. Brooke, who is also a bodybuilder, fitness competitor, gymnast and model, has battled in the WWE ring since 2013. Currently, she is regularly featured on WWE Raw, a professional wrestling television program produced by WWE that airs live every Monday at 8PM Eastern Time on the USA Network.

Diaz stated, “At 39 with a world record under my belt, I’m what you’d call a ‘rare breed’, I’ve worked hard to get to where I am today, and I am always striving to be even better. Bespoke CBD products help me do that. I wake up feeling refreshed and ready to take on the day.”

Brooke added, “I, too, work hard at being the best version of myself every single day – rain or shine. Bespoke CBD is an important nutritional supplement that I have come to trust to aid me in achieving my daily wellness goals.”

About Bespoke Extracts, Inc.

At Bespoke Extracts, we believe in the power of the individual. So, we strive to tailor each CBD experience to make its benefits unique to you and your lifestyle. That means making sure you are confident that everything we deliver to you is safe, effective, and perfect for you. From the very beginning, we have hand-picked our producers to ensure only NSF-certified and USDA-certified organic hemp from some of the finest CBD growers in the United States. It is also why we use the industry standard for extraction to ensure the purest and most potent product on the market. And finally, it is why we strive to develop a long-term personal relationship with each and every one of our customers — including you — to help them determine their needs and wants and supply the exact right solution for them. For more information, please visit www.bespokeextracts.com.

FORWARD-LOOKING STATEMENT

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management’s current expectations include those risks and uncertainties relating to our competitive position, the industry environment, potential growth opportunities, and the effects of regulation and events outside of our control, such as natural disasters, wars or health epidemics. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

No statement in this press release has been evaluated by the Food and Drug Administration. The efficacy of Bespoke’s products has not been confirmed by FDA-approved research. Our products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from healthcare practitioners. Please consult your health care professional about potential interactions or other possible complications before using any Bespoke Extract product. Bespoke Extracts, Inc. shall not be held liable for any medical claims made by customer testimonials.

For more information, please contact:

Bespoke Extracts, Inc.

Phone: 888-575-6738
Email: [email protected]
Web:  www.bespokeextracts.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/6722a167-bf3e-4a78-b45e-0f87e0c2d6a5

https://www.globenewswire.com/NewsRoom/AttachmentNg/c6521646-181e-4d99-acfb-edefde324550

https://www.globenewswire.com/NewsRoom/AttachmentNg/2ad6170e-6629-441e-b5aa-2aa61e89faa3



Posted on

Catalent, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference

Catalent, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J.–(BUSINESS WIRE)–
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executiveleadership team will virtually present at the 39th Annual J.P. Morgan Healthcare Conference at 8:20 a.m. ET on January 11, 2021.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs more than 14,000 people, including approximately 2,500 scientists, at more than 40 facilities across four continents and in fiscal 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, please visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

Investor Contact:

Paul Surdez, Catalent, Inc.

(732) 537-6325

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Health Genetics Clinical Trials General Health Pharmaceutical Biotechnology

MEDIA:

Posted on

B3 confirms JBS in the Carbon Efficient Index

PR Newswire

Index takes into account the commitment of companies to greenhouse gas reduction targets

SÃO PAULO, Jan. 6, 2021 /PRNewswire/ — JBS S.A. (the “Company” or “JBS” – B3: JBSS3; OTCQX: JBSAY) in accordance with the terms of CVM Instruction No. 358, dated January 3, 2002, as amended, communicates to its shareholders and to the market in general that once again it was announced as one of the companies selected to be part of the Carbon Efficient Index (“ICO2”) of the B3, which takes into account the commitment of companies to greenhouse gas reduction targets.

The 2021 edition is the first to encompass companies listed on the IBrX 100 that formally submitted their greenhouse gas emissions inventories to B3. Previously, only those companies that were part of the IBrX 50, that is, the holders of the 50 most exchange-traded shares were invited.

JBS has received important acknowledgements in sustainability

A presence in the Carbon Efficient Index (ICO2) portfolio of B3 is not the only sustainability acknowledgement JBS has received. CDP, the largest and most respected global platform for corporate sustainability information, disclosed on December 8, the results of the reports for 2019, which showed that JBS had advanced in the criteria assessed, occupying the leading position among the Brazilian companies in the Food, Beverage & Tobacco sector.

The Company was assessed on three fronts:  Climate Change; Water Security; and Forests, the latter being subdivided into the categories Wood, Cattle and Soybean.  In 2020, JBS rose from B to A- in Climate Change, reaching leadership level in the issue, and from B- to B in Forests: Soybean, maintaining score B in the other items analyzed.

The advance in the ranking of the Coller FAIRR Protein Producer Index, published in November 2020, was another recent important acknowledgement received by JBS. The Company jumped eight positions in the overall classification (the highest among Brazilian companies listed on B3), growth that clearly demonstrates the commitment of JBS to advance its sustainable practices and transparency.

“This is a very significant validation and a clear demonstration that we are working hard on the transition to the low-carbon economy, in addition to providing the market with increasingly transparent data”, points out Márcio Nappo, Sustainability director of JBS.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/b3-confirms-jbs-in-the-carbon-efficient-index-301202013.html

SOURCE JBS

Posted on

PCTEL Announces mmWave Transmitter for 5G In-Building Network Design and Testing

PCTEL Announces mmWave Transmitter for 5G In-Building Network Design and Testing

BLOOMINGDALE, Ill.–(BUSINESS WIRE)–
PCTEL, Inc. (Nasdaq: PCTI), a leading global provider of wireless technology, announced its new TX2440 mmWave Transmitter, a portable Continuous Wave (CW) transmitter for in-building and outdoor 5G network design.

5G mmWave networks have unique propagation and reflection characteristics, making coverage difficult to predict. The PCTEL® TX2440 transmitter mimics the propagation profiles of 5G mmWave signals, enabling real-world coverage testing prior to deployment. With data from CW testing, engineers can efficiently plan and design in-building and outdoor networks, reducing the cost of delivering effective 5G coverage.

“As demand for 5G service continues to rise, network engineers need tools that can help them expand the 5G footprint to key venues and other high-density environments,” said Rishi Bharadwaj, PCTEL’s Chief Operating Officer. “The TX2440 transmitter reinforces PCTEL’s leadership in the 5G market with a new test and measurement solution that makes it easier for mobile network operators and venue owners to deploy mmWave 5G coverage with confidence,” added Bharadwaj.

Key features include:

  • User-selectable 24-40 GHz transmission
  • Small, lightweight form factor
  • High performance mmWave antennas
  • Up to 5 hours continuous transmission with optional hot swappable battery pack system

During CW testing, signals from the TX2440 transmitter can be accurately measured using a portable PCTEL HBflex™ scanning receiver. PCTEL’s SeeHawk® data collection and reporting software enables users to view coverage data immediately or easily export it to leading network design and post processing tools. HBflex scanning receivers and SeeHawk software can also be used to test 5G mmWave and sub-6 GHz coverage and signal quality throughout the network lifecycle.

About PCTEL

PCTEL is a leading global provider of wireless technology, including purpose-built Industrial IoT devices, antenna systems, and test and measurement solutions. Trusted by our customers for over 25 years, we solve complex wireless challenges to help organizations stay connected, transform, and grow.

For more information, please visit our website at https://www.pctel.com/.

PCTEL®, SeeHawk®, and HBflex™ are registered trademarks or trademarks of PCTEL, Inc. © 2020 PCTEL, Inc. All rights reserved.

 

PCTEL Company Contact

Suzanne Cafferty

Vice President, Global Marketing

PCTEL, Inc.

(630) 339-2107

[email protected]

PCTEL Investor Relations Contact

Phillip Kupper

Three Part Advisors, LLC

(817) 778-8339

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Telecommunications Satellite Networks Internet Hardware Technology Semiconductor Mobile/Wireless

MEDIA:

Logo
Logo
Posted on

Morguard North American Residential REIT Announces Normal Course Issuer Bid

Canada NewsWire

MISSISSAUGA, ON, Jan. 6, 2021 /CNW/ – Morguard North American Residential Real Estate Investment Trust (TSX: MRG.UN) (the “REIT”) announced today that the Toronto Stock Exchange has accepted its notice of intention to make a normal course issuer bid through the facilities of the TSX and/or alternative Canadian trading systems.

The notice provides that the REIT may, during the twelve month period commencing January 8, 2021 and ending January 7, 2022, purchase for cancellation up to 2,955,913 units (“Units”) in total, being approximately 10% of the public float of outstanding Units.  The daily repurchase restriction for the Units is 13,807.  Additionally, the REIT may purchase for cancellation up to $8,048,000 principal amount of the 4.50% Convertible Unsecured Subordinated Debentures due March 31, 2023 (TSX:MRG.DB.A) (“Debentures”) being 10% of the public float of outstanding Debentures.  The daily repurchase restriction for the Debentures is $8,253.

The price which the REIT will pay for any such Units and Debentures will be the market price at the time of acquisition.  The actual number of Units and Debentures which may be purchased and the timing of any such purchases will be subject to compliance with the TSX guidelines.

Under the current normal course issuer bid expired on December 20, 2020, the REIT was approved to purchase up to 2,953,852 Units and $8,050,000 principal amount of Debentures through the facilities of the TSX and/or alternative Canadian trading systems.  No Units were purchased for cancellation and no Debentures were purchased for cancellation during the last twelve months.  As of December 31, 2020, there were 39,019,827 Units of the REIT outstanding with an average daily trading volume for the prior six months of 55,230.  Additionally, as of December 31, 2020 there were $85,500,000 principal amount Debentures of the REIT outstanding with an average daily trading volume for the prior six months of $33,015.

The REIT believes that, from time to time, its Units and Debentures trade in a price range which does not adequately reflect the value of such Units and Debentures in relation to the business of the REIT and its future business prospects.  As a result, depending upon future price movements and other factors, the REIT believes that its outstanding Units and Debentures may represent an attractive investment for itself.  Furthermore, the purchases may benefit all persons who continue to hold Units by increasing their equity interest in the REIT.  All Units and Debentures purchased by the REIT under the normal course issuer bid will be cancelled.

About Morguard North American Residential REIT

The REIT is an unincorporated, open-ended real estate investment trust which owns, through a limited partnership, interests in Canadian residential apartment communities, located in Alberta and Ontario, and U.S. residential apartment communities located in Colorado, Texas, Louisiana, Illinois, Georgia, Florida, North Carolina, Virginia and Maryland.

For more information, please visit Morguard.com.

SOURCE Morguard North American Residential Real Estate Investment Trust

Posted on

Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer

Everest to initiate trial in China as part of global Phase 3 TROPiCS-04

PR Newswire

SHANGHAI, Jan. 6, 2021 /PRNewswire/ — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People’s Republic of China has approved a Clinical Trial Application (CTA) for sacituzumab govitecan-hziy for the treatment of patients with metastatic urothelial cancer (mUC).

With this CTA, Everest Medicines plans to enroll patients in China as part of the Phase 3, global, multicenter, open-label randomized controlled TROPiCS-04 trial. The trial will evaluate sacituzumab govitecan-hziy compared with standard of care chemotherapeutic options in subjects with metastatic or locally advanced unresectable urothelial cancer who have progressed after prior therapy with a platinum-based regimen and anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy.  Subjects will be randomized to receive either sacituzumab govitecan-hziy or Treatment of Physician’s Choice (TPC), including paclitaxel, docetaxel, and vinflunine.

Positive results from the pivotal Phase 2 TROPHY U-01 study of sacituzumab govitecan-hziy in 113 mUC patients, presented at the ESMO 2020 annual conference, confirmed earlier study results showing sacituzumab govitecan-hziy has significant activity and is safe in patients with heavily pretreated mUC who progressed on both platinum-based chemotherapy and checkpoint inhibitors (CPI). Results from the study showed that sacituzumab govitecan-hziy achieved a 27% overall response rate (ORR) and a median duration of response (DOR) of 5.9 months in heavily pre-treated patients with mUC. Sacituzumab govitecan-hziy has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in this indication.

“Based on the compelling results generated to date, we believe that sacituzumab govitecan-hziy has the potential to offer patients with mUC a new treatment option, which may advance current standards of care and treatment,” said Yang Shi, Chief Medical Officer for Oncology at Everest Medicines. “Urothelial cancer is one of the most common urologic malignancies in China, with both incidence and mortality rates gradually increasing in recent years. We look forward to working with investigators and patients to initiate this study in China.”

About Urothelial Cancer

Urothelial cancer is a type of cancer that begins in urothelial cells that line the urethra, bladder, ureters, renal pelvis, and some other organs that make up the urinary system. According to Frost & Sullivan, in 2019, the incidence of urothelial cancer reached 76.4 thousand in China. 

About Sacituzumab Govitecan-Hziy

Sacituzumab govitecan-hziy is a first-in-class, antibody-drug conjugate (ADC) directed at TROP-2, a membrane antigen that is over-expressed in many common epithelial cancers. Under a licensing agreement with Gilead Sciences, Inc., Everest Medicines has exclusive rights to develop, register, and commercialize sacituzumab govitecan-hziy for all cancer indications in Greater China, South Korea, and certain Southeast Asian countries.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at www.everestmedicines.com.

For further information, please contact:

Everest Medicines
Media in US and Europe:
Darcie Robinson
Vice President
Westwicke PR
(203) 919-7905
[email protected]

Media in China:
Edmond Lococo
Managing Director

ICR Asia
+86 (10) 6583-7510
[email protected]  

Cision View original content:http://www.prnewswire.com/news-releases/everest-medicines-announces-cta-approval-by-china-nmpa-for-phase-3-trial-of-sacituzumab-govitecan-hziy-for-metastatic-urothelial-cancer-301202010.html

SOURCE Everest Medicines

Posted on

Crestwood Midstream Announces Tender Offer for Any and All of Its 6.25% Senior Notes Due 2023

Crestwood Midstream Announces Tender Offer for Any and All of Its 6.25% Senior Notes Due 2023

HOUSTON–(BUSINESS WIRE)–
Crestwood Midstream Partners LP (“CMLP”), a wholly-owned subsidiary of Crestwood Equity Partners LP (NYSE: CEQP), announced today that it has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of its outstanding 6.25% Senior Notes due 2023 (the “2023 Notes”). As of December 31, 2020, there was $687,190,000 aggregate principal amount of the 2023 Notes outstanding. The Tender Offer is being made pursuant to an offer to purchase, dated today, and a related notice of guaranteed delivery. The Tender Offer will expire at 5:00 p.m., New York City time, on January 13, 2021, unless extended (the “Expiration Time”). Tendered 2023 Notes may be withdrawn at any time before the Expiration Time.

Holders of 2023 Notes that are validly tendered (and not validly withdrawn) at or prior to the Expiration Time, or who deliver to the tender and information agent a properly completed and duly executed notice of guaranteed delivery and subsequently deliver such 2023 Notes, each in accordance with the instructions described in the offer to purchase, will receive $1,008.40 per $1,000 principal amount of the 2023 Notes accepted for purchase. In addition, all holders of 2023 Notes accepted for purchase will receive accrued and unpaid interest from and including the last interest payment date up to, but not including, the settlement date.

The Tender Offer is contingent upon, among other things, CMLP’s successful completion of a proposed debt financing transaction, the gross proceeds of which will be at least $700 million (the “Financing Condition”). The Tender Offer is not conditioned on any minimum amount of 2023 Notes being tendered. CMLP may amend, extend or terminate the Tender Offer, in its sole discretion.

The Tender Offer is being made pursuant to the terms and conditions contained in the offer to purchase and related notice of guaranteed delivery, copies of which are available at www.dfking.com/cmlp or may be requested from the information agent for the Tender Offer, D.F. King & Co., Inc., by telephone at (866) 416-0553 (toll free) or, for banks and brokers, (212) 269-5550, and by email at [email protected].

CMLP has retained RBC Capital Markets, LLC to serve as lead dealer manager and Wells Fargo Securities, LLC to serve as co-dealer manager for the Tender Offer. Persons with questions regarding the Tender Offer should contact the lead dealer manager for the Tender Offer, RBC Capital Markets, LLC, at (877) 381-2099 (toll free) or (212) 618-7843.

This news release does not constitute an offer to purchase or the solicitation of an offer to sell the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

Forward-Looking Statements

This press release may include certain statements concerning expectations for the future that are forward-looking statements as defined by federal securities law. Such forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that are difficult to predict and many of which are beyond management’s control. These risks and assumptions are described in CMLP’s filings with the United States Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management’s view only as of the date made. We undertake no obligation to update any forward-looking statement, except as otherwise required by law.

About Crestwood Midstream Partners LP

Houston, Texas, based CMLP is a limited partnership and wholly-owned subsidiary of CEQP that owns and operates midstream businesses in multiple shale resource plays across the United States. CMLP is engaged in the gathering, processing, treating, compression, storage and transportation of natural gas; storage, transportation, terminalling and marketing of NGLs; gathering, storage, terminalling and marketing of crude oil; and gathering and disposal of produced water.

Source: Crestwood Equity Partners LP

Crestwood Midstream Partners LP

Investor Contact

Josh Wannarka, 713-380-3081

[email protected]

Senior Vice President, Investor Relations,

ESG & Corporate Communications

Rhianna Disch, 713-380-3006

[email protected]

Director, Investor Relations

KEYWORDS: Texas Kansas United States North America

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo
Posted on

Crestwood Midstream Announces Private Offering of $700 Million of Senior Notes

Crestwood Midstream Announces Private Offering of $700 Million of Senior Notes

HOUSTON–(BUSINESS WIRE)–
Crestwood Midstream Partners LP (“CMLP”), a wholly-owned subsidiary of Crestwood Equity Partners LP (NYSE: CEQP), announced today its intention, subject to market and other conditions, to offer $700 million in aggregate principal amount of unsecured Senior Notes due 2029 (the “Notes”) in a private offering (the “Notes Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will be guaranteed on a senior unsecured basis by all of CMLP’s subsidiaries that guarantee its existing notes and the indebtedness under its revolving credit facility (the “Revolving Credit Facility”).

CMLP intends to use the net proceeds from the Notes Offering and borrowings under its Revolving Credit Facility to fund its obligations under the separately announced tender offer (the “Tender Offer”) for any and all of its outstanding 6.25% Senior Notes due 2023 (the “2023 Notes”), including fees and expenses in connection therewith. The Notes Offering is not conditioned on the consummation of the Tender Offer. The Tender Offer is conditioned on, among other things, the consummation of the Notes Offering.

The Notes and the related guarantees will be offered only to qualified institutional buyers in reliance on the exemption from registration set forth in Rule 144A under the Securities Act, and outside the United States to non-U.S. persons in reliance on the exemption from registration set forth in Regulation S under the Securities Act. The Notes and the related guarantees have not been registered under the Securities Act, or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from the Securities Act and applicable state securities or blue sky laws.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of the Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This notice is being issued pursuant to and in accordance with Rule 135(c) under the Securities Act.

Forward-Looking Statements

This press release may include certain statements concerning expectations for the future that are forward-looking statements as defined by federal securities law. Such forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that are difficult to predict and many of which are beyond management’s control. These risks and assumptions are described in CMLP’s filings with the United States Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management’s view only as of the date made. We undertake no obligation to update any forward-looking statement, except as otherwise required by law.

About Crestwood Midstream Partners LP

Houston, Texas, based CMLP is a limited partnership and wholly-owned subsidiary of CEQP that owns and operates midstream businesses in multiple shale resource plays across the United States. CMLP is engaged in the gathering, processing, treating, compression, storage and transportation of natural gas; storage, transportation, terminalling and marketing of NGLs; gathering, storage, terminalling and marketing of crude oil; and gathering and disposal of produced water.

Crestwood Midstream Partners LP

Investor Contact

Josh Wannarka, 713-380-3081

[email protected]

Senior Vice President, Investor Relations,

ESG & Corporate Communications

Rhianna Disch, 713-380-3006

[email protected]

Director, Investor Relations

KEYWORDS: United States North America Texas Kansas

INDUSTRY KEYWORDS: Maritime Utilities Transport Oil/Gas Alternative Energy Energy

MEDIA:

Logo
Logo
Posted on

IIROC Trade Resumption – AUSA

Canada NewsWire

VANCOUVER, BC, Jan. 6, 2021 /CNW/ – Trading resumes in:

Company: Australis Capital Inc.

CSE Symbol: AUSA

All Issues: Yes

Resumption (ET): 9:30 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)